Tricyclic Quinoline Derivatives for Selective 5-HT2C Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia and related disorders lack robust efficacy against negative and cognitive symptoms, and are associated with significant side effects such as extrapyramidal side effects and weight gain, due to their non-selective pharmacology affecting multiple receptor systems.
Innovation Solution
Development of tricyclic quinoline and quinoxaline derivatives that act as selective modulators, specifically agonists or partial agonists, of the 5-HT2C receptor to treat conditions related to 5-HT2C receptor modulation, minimizing affinity to adrenergic, histamine, and dopaminergic receptors to reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective pharmacology affecting multiple receptor systems is used to treat schizophrenia, then broad symptom coverage is achieved, but side effects such as extrapyramidal side effects and weight gain increase
Solution Approach 1:
The invention segments the pharmacological action by designing compounds with selective affinity for specific receptor subtypes (5-HT2A, 5-HT2C, 5-HT2B) while minimizing affinity for others (dopaminergic, adrenergic, histamine receptors). This segmentation allows targeted modulation of serotonin receptors involved in schizophrenia symptomatology without triggering side effects from non-selective receptor binding.
Solution Approach 2:
The compounds exhibit local quality through differential binding properties - high affinity and selectivity for specific 5-HT2 receptor subtypes in the mesolimbic and mesocortical pathways, while maintaining low affinity for other receptor systems. This localized pharmacological action concentrates therapeutic effects on target pathways while sparing non-target systems from adverse effects.
2Reliability
If atypical antipsychotics block mesolimbic dopaminergic neurotransmission to control positive symptoms, then positive symptoms are reduced, but negative and cognitive symptoms remain unaffected
Solution Approach 1:
Instead of blocking dopaminergic transmission as conventional antipsychotics do, the invention inverts the approach by selectively modulating 5-HT2C receptors. Since 5-HT2C receptors are densely expressed in mesocortical dopaminergic neurons and regulate dopamine release, this indirect modulation addresses negative and cognitive symptoms through serotonin-dopamine interaction rather than direct dopamine blockade.
Solution Approach 2:
The 5-HT2C receptor acts as an intermediary in the invention's mechanism. By selectively activating or modulating 5-HT2C receptors, the compounds indirectly influence dopaminergic neurotransmission in mesocortical pathways, providing a bridge between serotonin and dopamine systems to address negative and cognitive symptoms that direct dopamine blockade cannot treat.
3Object-affected harmful factors
If selective 5-HT2C receptor modulation is used to treat schizophrenia, then side effects are reduced, but robust efficacy against negative and cognitive symptoms must be achieved
Solution Approach 1:
The invention employs parameter changes by optimizing the compounds' pharmacological parameters - achieving high selectivity ratios (e.g., 100-fold or greater selectivity for 5-HT2C over other receptors), controlling affinity constants (Ki values in nanomolar range), and tuning in vivo potency. These parameter optimizations ensure both safety (reduced side effects) and efficacy (robust treatment response) are achieved simultaneously.
Data Source
AI summary
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.